Citizens Financial Group Inc. RI Acquires 13,488 Shares of Eli Lilly and Company (NYSE:LLY)

Citizens Financial Group Inc. RI lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 34.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,087 shares of the company’s stock after purchasing an additional 13,488 shares during the quarter. Eli Lilly and Company accounts for approximately 1.1% of Citizens Financial Group Inc. RI’s investment portfolio, making the stock its 18th biggest holding. Citizens Financial Group Inc. RI’s holdings in Eli Lilly and Company were worth $48,064,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Tidemark LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $29,000. Core Wealth Advisors Inc. raised its holdings in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the period. Lynx Investment Advisory bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 9,671 shares of Eli Lilly and Company stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the transaction, the insider now owns 97,574,139 shares in the company, valued at $88,077,248,051.13. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 451,900 shares of company stock worth $418,732,178. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Down 1.2 %

Shares of LLY opened at $923.71 on Monday. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53. The stock has a market capitalization of $877.92 billion, a price-to-earnings ratio of 136.04, a PEG ratio of 2.79 and a beta of 0.42. The stock has a fifty day moving average of $897.12 and a 200-day moving average of $833.89.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on LLY shares. Wells Fargo & Company increased their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Barclays increased their price objective on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their target price for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.